Impulse Dynamics announces appointment of Gerald M. Haines as Executive Vice President and Chief Financial Officer

ORANGEBURG, NY, July 8, 2019 – Impulse Dynamics, developer of the implantable Optimizer® Smart System for delivering CCM™ therapy, announced today the appointment of Gerald M. Haines to the position of Executive Vice President and Chief Financial Officer.

Mr. Haines brings to Impulse Dynamics a wealth of experience and proven track record in business, corporate finance and public markets, as well as acumen in strategic planning, M&A, and investor relations.

His career has spanned a series of positions of increasing scope and responsibility.  Most recently, he served as Chief Financial Officer at Mercury Systems, Inc. (NASDAQ: MRCY), where he also led Corporate Development, legal, and several other functions.  Prior to Mercury, Gerry served as Executive Vice President of Verenium Corporation, Executive Vice President of Strategic Affairs of Enterasys Networks, Inc., Senior Vice President of Cabletron Systems, Inc., the predecessor to Enterasys Networks; and Vice President of Applied Extrusion Technologies, Inc.

Mr. Haines holds a bachelor’s degree in Business Administration, magna cum laude, from Boston University and a law degree from Cornell University.

“We are excited to welcome Gerald Haines to Impulse Dynamics” said Dr. Simos Kediglou, the company’s CEO.  “Given the recent U.S. Food and Drug Administration approval of the Optimizer® Smart System, followed by several successful U.S. patient implants, we are gaining momentum and are eager to bring our breakthrough device to the large number of chronic heart failure patients in need of a new therapeutic alternative.  With the rapid growth we now expect to achieve comes the need to build the teams, processes and infrastructure necessary to drive strong business execution, and Gerald will play a key role in aligning us for success.”

 

About the Optimizer and CCM Therapy
CCM is the brand name for Cardiac Contractility Modulation, the non-excitatory electrical pulses delivered by the implantable Optimizer device during the absolute refractory period of the heart cycle to improve systolic contraction of the heart. The Optimizer System has been implanted in over 3,500 patients and is currently available in Europe, China, Brazil, India, and more than 40 other countries around the world. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials. The results have been published in over 80 papers in leading medical journals.

About Impulse Dynamics
Impulse Dynamics is focused on the development of electrical therapies for the treatment of chronic heart failure. As a global leader in cardiac medical innovation, Impulse Dynamics has operations in the United States, Europe, and Asia. For more information please visit www.impulse-dynamics.com.

Impulse Dynamics (USA), Inc.
30 Ramland Road South, Suite 204
Orangeburg, NY 10962